Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 1.00 |
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | RGS4 | P49798 | 10/20 | 0.82 |
| ▸ | RGS8 | P57771 | 10/20 | 0.82 |
| ▸ | PRKCA | P17252 | 2/20 | 0.78 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.67 |
| ▸ | CDK1 | P06493 | 1/20 | 0.67 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.67 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.67 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107221 | 0.91 | RGS4 (1.00) | GSK3BGSK3ARGS4RGS8PRKCA | |
| Krm-7777 SCHEMBL3384141 | 0.88 | GSK3B (1.00) | GSK3BGSK3ARGS4RGS8PRKCA | |
| SCHEMBL15212631 | 0.88 | GSK3B (0.78) | GSK3BGSK3ARGS4RGS8PRKCA | |
| SCHEMBL2106404 | 0.87 | GSK3B (0.75) | GSK3BGSK3ARGS4RGS8PRKCA | |
| SCHEMBL29239098 | 0.87 | GSK3B (0.75) | GSK3BGSK3ARGS4RGS8PRKCA | |
| SCHEMBL23763548 | 0.86 | GSK3B (0.77) | GSK3BGSK3ARGS4RGS8PRKCA | |
| SCHEMBL2107561 | 0.86 | GSK3B (1.00) | GSK3BGSK3ARGS4RGS8PRKCA | |
| SCHEMBL29239055 | 0.86 | GSK3B (0.76) | GSK3BGSK3ARGS4RGS8PRKCA | |
| SCHEMBL29239069 | 0.86 | GSK3B (0.74) | GSK3BGSK3ARGS4RGS8PRKCA | |
| SCHEMBL23763500 | 0.85 | GSK3B (0.77) | GSK3BGSK3ARGS4RGS8PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006045581-A1 | THE USE OF 1, 2, 4-THIADIAZOLIDINE-3, 5-DIONES AS PPAR ACTIVATORS | NEUROPHARMA, S.A. (ES) | 2006-05-04 | — | — | WO | claimed |
| CN-113827592-B | Application of thiadiazolidinedione compound in treating pathogenic infection | 中国科学院上海药物研究所 | 2024-06-18 | — | — | CN | disclosed |
| US-8158661-B2 | GSK-3 inhibitors | NOSCIRA, S.A. (ES) | 2012-04-17 | — | — | US | disclosed |
| EP-1586319-B1 | Thiadiazolidinones as GSK-3 inhibitors | NOSCIRA SA (ES) | 2009-10-21 | — | — | EP | disclosed |
| US-20090233971-A1 | GSK-3 Inhibitors | NOSCIRA, S.A. (ES) | 2009-09-17 | — | — | US | disclosed |
| US-7531561-B2 | GSK-3 inhibitors | NOSCIRA, S.A. (ES) | 2009-05-12 | — | — | US | disclosed |
| US-20080153886-A1 | Use Of Heterocyclic Compounds As Neurogenic Agents | NEUROPHARMA, S.A. (ES) | 2008-06-26 | — | — | US | disclosed |
| US-20080153886-A1 | Use Of Heterocyclic Compounds As Neurogenic Agents | NEUROPHARMA, S.A. (ES) | 2008-06-26 | — | — | US | disclosed |
| WO-2006045581-A1 | THE USE OF 1, 2, 4-THIADIAZOLIDINE-3, 5-DIONES AS PPAR ACTIVATORS | NEUROPHARMA, S.A. (ES) | 2006-05-04 | — | — | WO | disclosed |
| WO-2005097117-A1 | THIADIAZOLIDINONES AS GSK-3 INHIBITORS | NEUROPHARMA, S.A. (ES) | 2005-10-20 | — | — | WO | disclosed |
| EP-1586318-A1 | Thiadiazolidinones as GSK-3 inhibitors | Neuropharma S.A.U. (ES) | 2005-10-19 | — | — | EP | disclosed |
| EP-1586319-A1 | Thiadiazolidinones as GSK-3 inhibitors | Neuropharma S.A. (ES) | 2005-10-19 | — | — | EP | disclosed |
| US-20050222220-A1 | GSK-3 inhibitors | NEUROPHARMA, S.A. (ES) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233971-A1 | GSK-3 Inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885RGS4 4483/4885 |
| US-20050222220-A1 | GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885RGS4 4483/4885 |
| US-20080153886-A1 | Use Of Heterocyclic Compounds As Neurogenic Agents | GAP43, NGF, BDNF | GSK3B 848/4885GSK3A 945/4885RGS4 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.